- Home
- Publications
- Publication Search
- Publication Details
Title
Pulmonary toxicity of systemic lung cancer therapy
Authors
Keywords
-
Journal
RESPIROLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-07-30
DOI
10.1111/resp.13915
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The Relationship between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients with Advanced Non-Small Cell Lung Cancer
- (2019) Khinh Ranh Voong et al. Clinical Lung Cancer
- Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS
- (2019) Huan-huan Ji et al. CLINICAL DRUG INVESTIGATION
- The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment
- (2019) Yoshihiko Sakata et al. LUNG CANCER
- The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
- (2019) Karthik Suresh et al. JOURNAL OF CLINICAL INVESTIGATION
- Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
- (2019) Jacques Cadranel et al. European Respiratory Review
- Phase II study of nab‐paclitaxel + carboplatin for patients with non‐small‐cell lung cancer and interstitial lung disease
- (2019) Hirotsugu Kenmotsu et al. CANCER SCIENCE
- Retreatment With Osimertinib Following Pneumonitis
- (2018) Misako Nagasaka et al. Clinical Lung Cancer
- Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
- (2018) Monica Khunger et al. Clinical Lung Cancer
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients
- (2018) Chong Hyun Suh et al. LUNG CANCER
- Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease
- (2018) Osamu Kanai et al. Thoracic Cancer
- EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer
- (2018) Yasuo Oshima et al. JAMA Oncology
- Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities
- (2018) Karthik Suresh et al. CHEST
- Pneumonitis in Non-Small Cell Lung Cancer patients receiving Immune Checkpoint Immunotherapy: incidence and risk factors
- (2018) Karthik Suresh et al. Journal of Thoracic Oncology
- Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
- (2018) Jun Yeun Cho et al. LUNG CANCER
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations
- (2018) Hisao Imai et al. LUNG CANCER
- Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis
- (2018) Teppei Yamaguchi et al. LUNG CANCER
- The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis
- (2018) Ke Ma et al. Frontiers in Pharmacology
- Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy
- (2018) Karthik Suresh et al. Journal of Thoracic Oncology
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- (2017) Jarushka Naidoo et al. JOURNAL OF CLINICAL ONCOLOGY
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis
- (2017) Peng-Fei Cui et al. Therapeutics and Clinical Risk Management
- Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
- (2017) Sarah Chuzi et al. Cancer Management and Research
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
- (2016) Mizuki Nishino et al. JAMA Oncology
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
- (2016) Noha Abdel-Wahab et al. PLoS One
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
- (2015) J. Naidoo et al. ANNALS OF ONCOLOGY
- Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis
- (2015) Omar Abdel-Rahman et al. Future Oncology
- A Commentary on Interstitial Pneumonitis Induced by Docetaxel: Clinical Cases and Systematic Review of the Literature
- (2015) Giovenzio Genestreti et al. TUMORI
- A Commentary on Interstitial Pneumonitis Induced by Docetaxel: Clinical Cases and Systematic Review of the Literature
- (2015) Giovenzio Genestreti et al. TUMORI JOURNAL
- Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer
- (2014) Akihiko Gemma et al. CANCER SCIENCE
- Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials
- (2014) Wei-Xiang Qi et al. JOURNAL OF CHEMOTHERAPY
- Interstitial Lung Disease Associated with Gefitinib in Japanese Patients with EGFR-mutated Non-small-cell Lung Cancer: Combined Analysis of Two Phase III Trials (NEJ 002 and WJTOG 3405)
- (2013) Hiroaki Akamatsu et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials
- (2011) Daniel Binder et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience
- (2010) Katsuyuki Hotta et al. Journal of Thoracic Oncology
- Pulmonary toxicity in patients receiving docetaxel chemotherapy
- (2009) Perran F. Yumuk et al. MEDICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started